AAPL 208.1978 -0.5171% MSFT 387.475 -1.1165% NVDA 106.615 -3.9591% GOOGL 159.045 -1.7998% GOOG 160.825 -1.8462% AMZN 185.38 -1.9102% META 544.82 -0.4477% AVGO 188.44 -2.0124% LLY 865.67 -2.1333% TSLA 277.4 -2.6496% TSM 161.02 -2.4712% V 336.0 0.2476% JPM 241.245 -0.9464% UNH 416.63 -0.4801% NVO 62.33 0.4027% WMT 94.76 -0.347% LVMUY 114.46 -0.0524% XOM 107.98 -0.5434% LVMHF 572.0 -0.3484% MA 532.3622 -0.2095%
Last update at 2025-04-28T16:56:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Mon 14 Apr 25, 11:00 AMWhy Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday?
Thu 10 Apr 25, 01:25 PMIs Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?
Sun 02 Mar 25, 05:24 PMIronwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ...
Fri 28 Feb 25, 07:14 AMCalculating The Fair Value Of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Thu 23 Jan 25, 12:30 PMHere’s Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD)
Fri 20 Dec 24, 02:15 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 252.42M | 200.66M | 108.86M | 58.94M | -282.36800M |
| Minority interest | - | - | - | - | - |
| Net income | 175.06M | 528.45M | 106.18M | -15.31400M | -282.36800M |
| Selling general administrative | 115.99M | 111.13M | 140.00M | 172.45M | 241.29M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 410.60M | 413.75M | 386.39M | 404.54M | 313.89M |
| Reconciled depreciation | 1.42M | 1.52M | 3.56M | 5.58M | 14.22M |
| Ebit | 250.34M | 232.26M | 142.94M | 120.12M | -102.01700M |
| Ebitda | 259.84M | 232.94M | 159.85M | 120.42M | -93.90600M |
| Depreciation and amortization | 9.50M | 0.68M | 16.91M | 0.30M | 8.11M |
| Non operating income net other | 9.68M | -0.45200M | -4.60100M | -24.57800M | -5.75200M |
| Operating income | 250.34M | 232.26M | 142.94M | 120.12M | -238.89200M |
| Other operating expenses | 160.26M | 181.54M | 231.20M | 311.37M | 448.66M |
| Interest expense | 7.60M | 31.15M | 29.48M | 36.60M | 34.73M |
| Tax provision | 77.36M | -327.79100M | 2.69M | - | - |
| Interest income | 9.50M | 0.73M | 1.50M | 2.86M | 2.99M |
| Net interest income | 1.90M | -30.42400M | -27.97400M | -33.74000M | -34.73300M |
| Extraordinary items | - | - | - | -37.43800M | -88.22200M |
| Non recurring | - | - | 15.38M | 3.62M | 167.69M |
| Other items | - | - | - | - | - |
| Income tax expense | 77.36M | -327.79100M | 2.69M | 74.26M | -5.75200M |
| Total revenue | 410.60M | 413.75M | 389.52M | 428.41M | 346.64M |
| Total operating expenses | 160.26M | 181.54M | 228.06M | 287.49M | 415.90M |
| Cost of revenue | 0.00000M | 0.00000M | 3.14M | 23.88M | 32.75M |
| Total other income expense net | 2.08M | -31.60200M | -34.07900M | -61.18000M | -145.61800M |
| Discontinued operations | - | - | - | -37.43800M | -88.22200M |
| Net income from continuing ops | 175.06M | 528.45M | 106.18M | 58.94M | -282.36800M |
| Net income applicable to common shares | 175.06M | 528.45M | 106.18M | 21.50M | -282.36800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 471.07M | 1100.52M | 1126.93M | 559.24M | 402.75M |
| Intangible assets | 3.68M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 12.01M | 7.71M | 11.05M | 10.92M | 11.94M |
| Total liab | 817.37M | 448.14M | 521.02M | 496.60M | 496.00M |
| Total stockholder equity | -346.29500M | 652.38M | 605.91M | 62.64M | -93.25100M |
| Deferred long term liab | - | - | - | 12.09M | 24.26M |
| Other current liab | 64.34M | 21.98M | 1.32M | 0.54M | 33.42M |
| Common stock | 0.16M | 0.15M | 0.16M | 0.16M | 0.16M |
| Capital stock | 0.16M | 0.15M | 0.16M | 0.16M | 0.16M |
| Retained earnings | -1698.61500M | -696.37600M | -937.60800M | -1466.05600M | -1572.23200M |
| Other liab | - | 9.77M | 3.50M | 13.31M | 24.99M |
| Good will | - | - | - | 0.79M | 0.79M |
| Other assets | 0.00000M | 299.58M | 358.78M | 54.47M | 64.94M |
| Cash | 92.15M | 656.20M | 620.13M | 362.56M | 177.02M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 276.10M | 25.52M | 161.70M | 32.71M | 40.93M |
| Current deferred revenue | 1.24M | - | 39.46M | 28.38M | 0.88M |
| Net debt | 623.38M | -240.28800M | -144.32700M | 91.14M | 254.20M |
| Short term debt | 202.69M | 3.06M | 119.98M | 3.13M | 1.15M |
| Short long term debt | 199.56M | - | 116.86M | - | - |
| Short long term debt total | 715.54M | 415.92M | 475.80M | 453.70M | 431.22M |
| Other stockholder equity | 1355.19M | 1348.60M | 1543.36M | 1528.54M | 1478.82M |
| Property plant equipment | - | 6.29M | 22.93M | 8.93M | 12.43M |
| Total current assets | 233.29M | 780.63M | 745.23M | 495.84M | 306.85M |
| Long term investments | - | 14.59M | 24.00M | 36.47M | 63.96M |
| Net tangible assets | - | 668.98M | 605.91M | 82.96M | -71.95400M |
| Short term investments | - | - | - | - | - |
| Net receivables | 129.12M | 115.46M | 114.04M | 122.35M | 117.25M |
| Long term debt | 498.31M | 396.25M | 337.33M | 430.26M | 407.99M |
| Inventory | 0.00000M | 1.25M | - | 0.00000M | 0.65M |
| Accounts payable | 7.83M | 0.48M | 0.94M | 0.66M | 5.49M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.03100M | - | - | -11.80500M | -10.08200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.15M | 0.16M | 0.16M | 0.16M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -696.37600M | -937.60800M | -1466.05600M | -1572.23200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.61M | 15.92M | 25.48M | 37.11M | 64.94M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 237.78M | 319.89M | 381.70M | 63.40M | 95.90M |
| Capital lease obligations | 17.67M | 19.66M | 21.61M | 23.45M | 23.23M |
| Long term debt total | - | 396.25M | 337.33M | 430.26M | 407.99M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.13600M | -0.26500M | -1.84200M | -11.14400M | 95.92M |
| Change to liabilities | -7.93000M | 10.08M | -7.55200M | -33.18300M | 8.96M |
| Total cashflows from investing activities | -0.13600M | -0.26500M | -1.84200M | -11.14400M | 88.87M |
| Net borrowings | -120.69900M | -120.69900M | -120.69900M | 16.25M | -1.82400M |
| Total cash from financing activities | -237.55300M | -4.55000M | 18.55M | -1.18500M | 30.07M |
| Change to operating activities | 2.94M | 12.66M | 2.72M | 0.72M | -1.56700M |
| Net income | 175.06M | 528.45M | 106.18M | 21.50M | -282.36800M |
| Change in cash | 36.07M | 257.08M | 185.54M | -1.60400M | 48.06M |
| Begin period cash flow | 621.86M | 364.78M | 179.24M | 180.85M | 132.79M |
| End period cash flow | 657.94M | 621.86M | 364.78M | 179.24M | 180.85M |
| Total cash from operating activities | 273.76M | 261.89M | 168.84M | 10.72M | -70.88200M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1.42M | 1.52M | 3.56M | 5.58M | 14.22M |
| Other cashflows from investing activities | - | - | - | -3.95500M | 1.56M |
| Dividends paid | 111.16M | - | - | - | - |
| Change to inventory | 0.00000M | 0.00000M | 0.65M | 0.72M | -0.80600M |
| Change to account receivables | 7.99M | 7.71M | 4.09M | -68.89300M | 1.21M |
| Sale purchase of stock | -126.39400M | -24.13100M | 18.55M | 13.60M | 32.06M |
| Other cashflows from financing activities | 111.16M | 19.58M | 18.55M | 155.22M | 31.90M |
| Change to netincome | 91.49M | -321.69200M | 19.47M | 90.00M | 104.43M |
| Capital expenditures | 0.14M | 0.27M | 1.84M | 7.19M | 8.62M |
| Change receivables | 7.99M | 7.71M | 4.09M | -68.89300M | 1.21M |
| Cash flows other operating | 3.87M | 11.88M | 20.17M | -23.87100M | 66.03M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 36.07M | 257.08M | 185.54M | -1.60400M | 48.06M |
| Change in working capital | 2.82M | 17.73M | -0.94100M | -99.99300M | 7.62M |
| Stock based compensation | 27.05M | 22.28M | 31.18M | 31.28M | 43.98M |
| Other non cash items | 1.67M | 25.21M | 22.26M | 16.42M | -13.44400M |
| Free cash flow | 273.63M | 261.63M | 166.99M | 3.54M | -79.50300M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc |
0.04 4.63% | 0.93 | - | 12.33 | 2.79 | 2.59 | 4.19 | -2.0077 |
| ZTS Zoetis Inc |
-0.425 0.28% | 153.04 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.84 3.06% | 28.27 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
5.46 4.10% | 138.65 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.12 0.83% | 15.15 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
100 Summer Street, Boston, MA, United States, 02110
| Name | Title | Year Born |
|---|---|---|
| Ms. Julie H. McHugh | Exec. Chairman | 1964 |
| Mr. Thomas A. McCourt | CEO & Director | 1957 |
| Mr. Sravan Kumar Emany | Sr. VP, Principal Financial Officer & CFO | 1978 |
| Mr. Jason Rickard | Sr. VP & COO | 1971 |
| Mr. John Minardo | Sr. VP, Chief Legal Officer & Sec. | 1976 |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Sr. VP and Head of Research & Drug Devel. | 1959 |
| Mr. Ronald Silver | Corp. Controller & Principal Accounting Officer | 1982 |
| Mr. Marcel Moulaison | VP of Technical Operations | NA |
| Ms. Beth Calitri | Head of Corp. Communications & Media Relations | NA |
| Mr. Mike Nanfito | VP of Sales & Sales Excellence | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...